• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEF 14A filed by McKesson Corporation

    6/20/25 4:19:35 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care
    Get the next $MCK alert in real time by email

    Unavailable

    Get the next $MCK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MCK

    DatePrice TargetRatingAnalyst
    12/4/2024$630.00Neutral
    Mizuho
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    2/26/2024$600.00Outperform
    Leerink Partners
    1/3/2024$537.00Overweight
    Barclays
    12/14/2023$502.00Equal Weight
    Wells Fargo
    More analyst ratings

    $MCK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    McKesson Corporation Reports Fiscal 2026 First Quarter Results and Raises Full Year Adjusted EPS Guidance

    McKesson Corporation (NYSE:MCK) has released its fiscal 2026 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 6 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inv

    8/6/25 4:10:00 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Raises Quarterly Dividend by 15% to $0.82 Per Share

    The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.82 per share of common stock, a 15% increase from $0.71 per share in the prior quarter. The dividend will be payable on October 1, 2025, to stockholders of record on September 2, 2025. "McKesson continues our long-standing track record of returning capital to shareholders, marking our ninth consecutive annual dividend increase," said Brian Tyler, chief executive officer. "These actions reflect our confidence in the strength of our business and reinforces our commitment to delivering long-term value to shareholders." About McKesson Corporation McKesson Corporation is a diversified heal

    7/30/25 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Announces First Quarter Fiscal 2026 Earnings Release Date

    McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2026 financial results after market close on Wednesday, August 6, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to he

    6/26/25 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho resumed coverage on McKesson with a new price target

    Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00

    12/4/24 7:43:38 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously

    11/7/24 6:29:13 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded McKesson from Outperform to Neutral and set a new price target of $531.00 from $603.00 previously

    9/24/24 8:19:53 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tyler Brian S. sold $8,085,677 worth of shares (11,930 units at $677.76), decreasing direct ownership by 43% to 15,942 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    8/19/25 10:20:40 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SVP, Controller & CAO Rutledge Napoleon B Jr sold $218,347 worth of shares (329 units at $663.67), decreasing direct ownership by 33% to 657 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    8/11/25 4:52:21 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Director Gerberding Julie L.

    4 - MCKESSON CORP (0000927653) (Issuer)

    7/31/25 6:38:18 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    SEC Filings

    View All

    SEC Form 10-Q filed by McKesson Corporation

    10-Q - MCKESSON CORP (0000927653) (Filer)

    8/6/25 5:30:47 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MCKESSON CORP (0000927653) (Filer)

    8/6/25 4:06:31 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - MCKESSON CORP (0000927653) (Filer)

    8/1/25 8:54:21 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Financials

    Live finance-specific insights

    View All

    McKesson Corporation Reports Fiscal 2026 First Quarter Results and Raises Full Year Adjusted EPS Guidance

    McKesson Corporation (NYSE:MCK) has released its fiscal 2026 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 6 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inv

    8/6/25 4:10:00 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Raises Quarterly Dividend by 15% to $0.82 Per Share

    The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.82 per share of common stock, a 15% increase from $0.71 per share in the prior quarter. The dividend will be payable on October 1, 2025, to stockholders of record on September 2, 2025. "McKesson continues our long-standing track record of returning capital to shareholders, marking our ninth consecutive annual dividend increase," said Brian Tyler, chief executive officer. "These actions reflect our confidence in the strength of our business and reinforces our commitment to delivering long-term value to shareholders." About McKesson Corporation McKesson Corporation is a diversified heal

    7/30/25 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Announces First Quarter Fiscal 2026 Earnings Release Date

    McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2026 financial results after market close on Wednesday, August 6, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to he

    6/26/25 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    2/13/24 5:09:38 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    1/25/24 1:48:52 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    2/10/22 8:27:59 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Leadership Updates

    Live Leadership Updates

    View All

    McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

    Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

    8/26/24 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

    10/4/23 4:05:00 PM ET
    $KRMD
    $MCK
    Medical/Dental Instruments
    Health Care
    Other Pharmaceuticals

    Gentherm Announces Dr. Ken Washington as New Independent Director

    NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol

    10/2/23 8:00:00 AM ET
    $AMZN
    $F
    $MCK
    Catalog/Specialty Distribution
    Consumer Discretionary
    Auto Manufacturing
    Industrials